Aliases & Classifications for Prostate Disease

Summaries for Prostate Disease

MedlinePlus : 41 the prostate is a gland in men. it helps make semen, the fluid that contains sperm. the prostate surrounds the tube that carries urine away from the bladder and out of the body. a young man's prostate is about the size of a walnut. it slowly grows larger with age. if it gets too large, it can cause problems. this is very common after age 50. the older men get, the more likely they are to have prostate trouble. some common problems are prostatitis - inflammation, usually caused by bacteria enlarged prostate (bph), or benign prostatic hyperplasia - a common problem in older men which may cause dribbling after urination or a need to go often, especially at night prostate cancer - a common cancer that responds best to treatment when detected early nih: national institute of diabetes and digestive and kidney diseases

MalaCards based summary : Prostate Disease, also known as prostatic diseases, is related to prostate cancer and prostatitis, and has symptoms including angina pectoris, tremor and prostatism. An important gene associated with Prostate Disease is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Endometrial cancer and Glucose / Energy Metabolism. The drugs Povidone and Povidone-iodine have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and lymph node, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

Wikipedia : 72 The prostate (from Ancient Greek προστάτης, prostates, literally \"one who stands before\",... more...

Related Diseases for Prostate Disease

Diseases related to Prostate Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 51)
id Related Disease Score Top Affiliating Genes
1 prostate cancer 26.1 AKR1C3 AMACR AR CYP19A1 FOLH1 KLK3
2 prostatitis 10.9
3 hole retinal cyst 10.6 AR KLK3
4 8p23.1 duplication syndrome 10.6 SRD5A1 SRD5A2
5 fibroma 10.5 FOLH1 KLK3
6 endometriosis 10.5 AR KLK3 SRD5A1
7 vaginal discharge 10.4 AR SRD5A2
8 osteogenesis imperfecta 10.3 AR CYP19A1
9 cutis laxa, autosomal recessive, type ia 10.3 HP PPARG SERPINA6
10 pepck 1 deficiency 10.3 AR SRD5A1 SRD5A2
11 prostate small cell carcinoma 10.2 AR KLK3
12 osteopathia striata with cranial sclerosis 10.2 AR CYP19A1 SRD5A1
13 tooth disease 10.2 AR SRD5A1 SRD5A2
14 glioblastoma proneural subtype 10.2 AR CYP19A1 KLK3
15 esophagus sarcoma 10.2 AR CYP19A1 KLK3
16 capillary disease 10.2 AR CYP19A1 KLK3
17 avoidant personality disorder 10.1 AR CYP19A1 KLK3
18 subglottis neoplasm 10.1 CYP19A1 HP
19 perinatal jaundice due to hepatocellular damage 10.1 AKR1C3 CYP19A1
20 thymic dysplasia 10.1 AMACR KLK3
21 condrodisplasia punctata rizomélica 10.1 AR CYP19A1 NR1H2
22 sphingolipidosis 10.1 AR CYP19A1
23 autoimmune disease of central nervous system 10.0 AR KLK3
24 pituitary carcinoma 10.0 AMACR KLK3
25 glycogen-rich clear cell breast carcinoma 10.0 AMACR KLK3
26 fibrosclerosis of breast 10.0 KLK3 SERPINA3
27 breast adenomyoepithelial adenosis 10.0 AMACR KLK3
28 gastrojejunal ulcer 10.0 AR CYP19A1 SRD5A2
29 intraventricular meningioma 9.9 AR CYP19A1 SRD5A2
30 androgen insensitivity, partial, with or without breast cancer 9.9 AR CYP19A1 SRD5A2
31 fibular collateral ligament bursitis 9.9 AMACR KLK3
32 mucinous adenocarcinoma 9.9 AMACR AR KLK3
33 adams-oliver syndrome 6 9.8 AMACR CYP19A1
34 prostate calculus 9.8
35 epilepsy, idiopathic generalized 11 9.8 AR CYP19A1 SRD5A1 SRD5A2
36 splenic infarction 9.6 AMACR AR FOLH1 KLK3
37 medullomyoblastoma 9.6 AMACR AR FOLH1 KLK3
38 bardet-biedl syndrome 9.6 AMACR AR FOLH1 KLK3
39 obesity 9.5
40 insulin-like growth factor i 9.5
41 myocardial infarction 9.4
42 breast cancer 9.4
43 male infertility 9.4
44 prostatic hypertrophy 9.4
45 rectal disease 9.4
46 papilledema 9.4
47 acromegaly 9.4
48 ischemia 9.4
49 infertility 9.4
50 endotheliitis 9.4

Comorbidity relations with Prostate Disease via Phenotypic Disease Network (PDN):


Prostate Cancer Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Prostate Disease:



Diseases related to Prostate Disease

Symptoms & Phenotypes for Prostate Disease

UMLS symptoms related to Prostate Disease:


angina pectoris, tremor, prostatism, equilibration disorder

MGI Mouse Phenotypes related to Prostate Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.96 AKR1C3 AMACR AR CYP19A1 GADD45A HBEGF
2 endocrine/exocrine gland MP:0005379 9.87 AR CYP19A1 GADD45A NR1H2 PPARG SRD5A1
3 liver/biliary system MP:0005370 9.7 AMACR AR CYP19A1 HP NR1H2 PPARG
4 renal/urinary system MP:0005367 9.43 AR CYP19A1 GADD45A HP PPARG SERPINA6
5 reproductive system MP:0005389 9.23 SRD5A1 SRD5A2 AKR1C3 AR CYP19A1 GADD45A

Drugs & Therapeutics for Prostate Disease

Drugs for Prostate Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 828)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Povidone Approved Phase 4 9003-39-8
2 Povidone-iodine Approved Phase 4 25655-41-8
3
Tamsulosin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106133-20-4 129211
4
Finasteride Approved Phase 4,Phase 3,Phase 2,Phase 1 98319-26-7 57363
5
Dutasteride Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 164656-23-9 152945 6918296
6
Bupivacaine Approved, Investigational Phase 4,Phase 1,Phase 2 2180-92-9, 38396-39-3 2474
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
8
Ethanol Approved Phase 4,Phase 2,Phase 1 64-17-5 702
9
Fesoterodine Approved Phase 4 286930-02-7, 286930-03-8 6918558
10
Goserelin Approved Phase 4,Phase 3,Phase 2,Phase 1 65807-02-5 47725 5311128
11
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
12
Doxazosin Approved Phase 4,Phase 3,Phase 2 74191-85-8 3157
13
Alfuzosin Approved, Investigational Phase 4,Phase 3,Phase 2 81403-80-7 2092
14
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
15
Bicalutamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 90357-06-5 56069 2375
16
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1 58-18-4 6010
17
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 171596-29-5 110635
18
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
19
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
20
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
21
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
22
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53714-56-0 3911 657181
23
Histamine Approved, Investigational Phase 4,Phase 2,Early Phase 1 75614-87-8, 51-45-6 774
24
Lenograstim Approved Phase 4,Phase 2,Phase 3,Phase 1 135968-09-1
25
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983
26
Flutamide Approved Phase 4,Phase 3,Phase 2,Phase 1 13311-84-7 3397
27
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 169590-42-5 2662
28
Silodosin Approved Phase 4,Phase 3,Phase 2 160970-54-7
29
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
30
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 85721-33-1 2764
31
Terazosin Approved Phase 4 63590-64-7 5401
32
Dihydrotachysterol Approved Phase 4,Phase 2 67-96-9 5281010 5311071
33
Levobupivacaine Approved Phase 4 27262-47-1 92253
34
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
35
Mivacurium Approved Phase 4 106791-40-6, 133814-19-4 5281042
36
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
37
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
38
Diphenhydramine Approved Phase 4,Phase 2,Phase 1 58-73-1, 147-24-0 3100
39
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
40
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
41
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
42
Ondansetron Approved Phase 4 99614-02-5 4595
43
Promethazine Approved Phase 4,Phase 2,Phase 1 60-87-7 4927
44
Ranitidine Approved Phase 4,Phase 2 66357-59-3, 66357-35-5 3001055
45
Etidronic acid Approved Phase 4,Phase 3 7414-83-7, 2809-21-4 3305
46
Prilocaine Approved Phase 4 721-50-6 4906
47 Mirabegron Approved Phase 4 223673-61-8
48
Cycloserine Approved Phase 4 68-41-7 401 6234
49
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2216-51-5 16666
50
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192

Interventional clinical trials:

(show top 50) (show all 3705)

id Name Status NCT ID Phase Drugs
1 A Prospective Trial of Povidone-iodine Suppository Before Transrectal Ultrasound Guided Prostate Biopsy Unknown status NCT02245334 Phase 4 Povidone-Iodine
2 Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia Unknown status NCT02034604 Phase 4 Naftofidil;Tamsulosin
3 A Study Comparing Photoselective Vaporization of the Prostate With the GreenLight XPS™ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia Unknown status NCT01218672 Phase 4
4 Kinetics of the Finasteride Prostate Induced Apoptosis Unknown status NCT00130767 Phase 4 finasteride
5 Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH) Unknown status NCT01301599 Phase 4 combination therapy;alpha blocker monotherapy;5 alpha reductase inhibitor monotherapy
6 Clinical Study to Assess the Influence of a Saw Palmetto Preparation in Patients With Benign Prostatic Hyperplasia (BPH) and Sexual Dysfunctions Unknown status NCT01021267 Phase 4 Saw palmetto berry extract
7 A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart Unknown status NCT00690950 Phase 4 Dutasteride
8 Low Dose Bupivacaine Spinal for Trans Uretral Prostatectomy. Unknown status NCT01861041 Phase 4 Heavy Bupivacaine;Isobaric Bupivacaine
9 Prostatic Artery Embolization Versus 532 nm Green Light PVP for Catheterized Patients Unknown status NCT02006303 Phase 4
10 Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients Unknown status NCT01736033 Phase 4 Tamsulosin;Finasteride;Placebo
11 An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia Unknown status NCT00605319 Phase 4 Toviaz (Fesoterodine)
12 Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy Unknown status NCT01379742 Phase 4
13 FINNPROSTATE Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer Unknown status NCT00293670 Phase 4 Goserelin (Zoladex)
14 Treatment of Localized Prostate Cancer With High Intensity Focused Ultrasound Using the Sonablate® 500 System in Canada Unknown status NCT00573586 Phase 4
15 Metformin And Longevity Unknown status NCT02511665 Phase 4 Metformin;Placebo
16 MR-Lymphography and Lymph Node Staging in Prostate Cancer Unknown status NCT00185029 Phase 4
17 Early Detection of Prostate Cancer by FACS Unknown status NCT00524823 Phase 4
18 Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer Unknown status NCT00906269 Phase 4 Sildenafil therapy plus post-NSRRP HBO2T;Sildenafil therapy plus sham post-NSRRP HBO2T
19 Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH) Unknown status NCT00922506 Phase 4 doxazosin plus tolterodine SR
20 Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications Unknown status NCT01876836 Phase 4
21 Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study Completed NCT00575913 Phase 4 Alfuzosin
22 Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement Completed NCT00648323 Phase 4 Doxazosin mysylate GITS
23 Treatment of Chronic Bacterial Prostatitis Completed NCT02130713 Phase 4 Third generation fluoroquinolone
24 Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) Patients Completed NCT02244229 Phase 4 Tamsulosin;Finasteride;Placebo
25 Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH) Completed NCT01259531 Phase 4 Silodosin
26 SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin Completed NCT00486785 Phase 4 Alfuzosin
27 ALF-ONE : ALFuzosin ONcE Daily Completed NCT00280605 Phase 4 Alfuzosin
28 PVP Compared to TURP for the Treatment of Benign Hyperplasia of the Prostate Completed NCT00527371 Phase 4
29 Holmium Laser Enucleation of Prostate(HOLEP) vs Greenlight(XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP) Completed NCT01494337 Phase 4
30 Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia Completed NCT01500057 Phase 4
31 KTP (Potassium-titanyl-phosphate) Laser Versus TUR-P (Transurethral Resection of Prostate) Completed NCT02011308 Phase 4
32 Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years Completed NCT02757963 Phase 4
33 Bipolar vs Monopolar Transurethral Resection of the Prostate (TURP) Completed NCT00199550 Phase 4
34 Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration Completed NCT02041767 Phase 4 Ertapenem
35 Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate Completed NCT00880672 Phase 4 dutasteride
36 A Trial Assessing Peri-procedure Chemoprophylaxis During Transrectal Prostate Needle Biopsy Completed NCT02423759 Phase 4 ciprofloxacin;ciprofloxacin and gentamycine;culture based chemoprophylaxis
37 A Long-Term Study Examining the Treatment of Benign Prostatic Hyperplasia With Photoselective Vaporization Completed NCT00465101 Phase 4
38 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin Completed NCT00401661 Phase 4 Alfuzosin
39 FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244255 Phase 4 FLOMAX® capsules;Ascending doses of HYTRIN® capsules
40 Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia Completed NCT00701779 Phase 4 Tamsulosin
41 Effect Of Dutasteride On Intraprostatic Dihydrotestosterone (DHT) Levels Completed NCT00062790 Phase 4 Dutasteride
42 Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia Completed NCT01757769 Phase 4 Silodosin
43 Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244242 Phase 4 Tamsulosin hydrochloride
44 Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study Completed NCT00427882 Phase 4 ALFUZOSIN
45 Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia) Completed NCT01604811 Phase 4 Permixon® 160 mg;Tamsulosine Arrow LP;Placebo matching Permixon® 160 mg;Placebo matching Tamsulosine Arrow LP
46 Once Daily Given Alfuzosin in the Treatment of BPH Completed NCT00637715 Phase 4 Alfuzosin
47 A Prospective Evaluation of the GreenLight Model 120 Laser Completed NCT00364585 Phase 4
48 Addition of Lidocaine to Levobupivacaine Reduces Intrathecal Block Duration Completed NCT01675895 Phase 4 Levobupivacaine lidocaine spinal anesthesia;levobupivacaine Spinal anesthesia
49 Prospective Sexual Function Study for BPH Subjects Completed NCT01777269 Phase 4 Dutasteride plus tamsulosin;Placebo
50 Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy Completed NCT00470834 Phase 4 dutasteride;placebo;bicalutamide

Search NIH Clinical Center for Prostate Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: prostatic diseases

Genetic Tests for Prostate Disease

Anatomical Context for Prostate Disease

MalaCards organs/tissues related to Prostate Disease:

39
Prostate, Bone, Lymph Node, Testes, Lung, Kidney, T Cells

Publications for Prostate Disease

Articles related to Prostate Disease:

(show top 50) (show all 170)
id Title Authors Year
1
Over-Expression of Activin-I^C Is Associated with Murine and Human Prostate Disease. ( 28116672 )
2017
2
Erratum: Comparative study of serum zinc concentrations in benign and malignant prostate disease: A Systematic Review and Meta-Analysis. ( 27436144 )
2016
3
Re: Testosterone Replacement Therapy on the Natural History of Prostate Disease. ( 27845125 )
2016
4
Comparative study of serum zinc concentrations in benign and malignant prostate disease: A Systematic Review and Meta-Analysis. ( 27170414 )
2016
5
Prostatectomy for benign prostate disease: open, laparoscopic and robotic techniques. ( 26497345 )
2015
6
Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease. ( 26171936 )
2015
7
The investigation of GSTP1, APC and RASSF1 gene promoter hypermethylation in urine DNA of prostate-diseased patients. ( 25665470 )
2015
8
Further evaluation of uPA and PAI-1 as biomarkers for prostatic diseases. ( 25323935 )
2015
9
Initial Evaluation of the Safety of Nanoshell-Directed Photothermal Therapy in the Treatment of Prostate Disease. ( 26296672 )
2015
10
Testosterone Replacement Therapy on the Natural History of Prostate Disease. ( 26077355 )
2015
11
MALDI MS profiling of post-DRE urine samples highlights the potential of I^-microseminoprotein as a marker for prostatic diseases. ( 24115268 )
2014
12
Evolution of primary care referrals to urology. Impact of a protocol on prostate disease and continuing education. ( 25554605 )
2014
13
Lycopene for the prevention and treatment of prostate disease. ( 24531784 )
2014
14
Androgens and prostate disease. ( 24407178 )
2013
15
Serum amyloid A, phospholipase Aa88-IIA and C-reactive protein as inflammatory biomarkers for prostate diseases. ( 24061501 )
2013
16
Current status of 5I+-reductase inhibitors in prostate disease management. ( 23614056 )
2013
17
Circulating Prostate Cells Found in Men with Benign Prostate Disease Are P504S Negative: Clinical Implications. ( 23690774 )
2013
18
Effect of microbubble-enhanced ultrasound on prostate permeability: a potential therapeutic method for prostate disease. ( 23414693 )
2013
19
Seminal plasma glycoproteins in male infertility and prostate diseases: is there a chance for glyco-biomarkers? ( 23061682 )
2013
20
Treatment for prostate disease should be uniform across the UK. ( 27794764 )
2012
21
Botulinum toxin A in prostate disease: a venom from bench to bed-side. ( 22409179 )
2012
22
Can a Gleason 6 or Less Microfocus of Prostate Cancer in One Biopsy and Prostate-Specific Antigen Level <10a88ng/mL Be Defined as the Archetype of Low-Risk Prostate Disease? ( 22848218 )
2012
23
Patient reported incontinence after radical prostatectomy is more common than expected and not associated with the nerve sparing technique: results from the Center for Prostate Disease Research (CPDR) database. ( 21826727 )
2012
24
Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-I+ and GPER signalling. ( 22233684 )
2012
25
Prostate disease risk factors among a New Zealand cohort. ( 23363810 )
2012
26
Risk of prostate cancer associated with benign prostate disease: a primary care case-control study. ( 22054323 )
2011
27
Cholesterol and benign prostate disease. ( 21862201 )
2011
28
Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. ( 21091976 )
2011
29
Correlation between age and Chromogranin A determination in prostate diseases. ( 22674297 )
2011
30
Detecting gene-gene interactions in prostate disease in African American men. ( 21992608 )
2011
31
The role of oestrogen in the pathogenesis of obesity, type 2 diabetes, breast cancer and prostate disease. ( 20535861 )
2010
32
N-glycosylation status of beta-haptoglobin in sera of patients with prostate cancer vs. benign prostate diseases. ( 19956848 )
2010
33
Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial. ( 21079217 )
2010
34
Serum free circulating DNA is a useful biomarker to distinguish benign versus malignant prostate disease. ( 20647404 )
2010
35
ACR appropriateness criteria on obstructive voiding symptoms secondary to prostate disease. ( 20362939 )
2010
36
5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications. ( 19030020 )
2009
37
A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits. ( 19267353 )
2009
38
Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. ( 19375853 )
2009
39
Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer. ( 19021204 )
2009
40
A new vision for the study of benign prostate disease: the NIDDK Prostate Research Strategic Plan. ( 19150562 )
2009
41
Evaluation of ischemia-modified albumin in myocardial infarction and prostatic diseases. ( 19375269 )
2009
42
High-fat diet, obesity and prostate disease: the ATX-LPA axis? ( 19204739 )
2009
43
The Center for Prostate Disease Research (CPDR): a multidisciplinary approach to translational research. ( 19720304 )
2009
44
Clinical guidelines: should 5 alpha-reductase inhibitors be used for prostate disease? ( 19578352 )
2009
45
Optimizing the management of prostate diseases: prostatitis and benign prostatic hyperplasia. Introduction. ( 18307677 )
2008
46
A novel splice variant of the nuclear coactivator p120 functions strongly for androgen receptor: characteristic expression in prostate disease. ( 18560202 )
2008
47
[Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy]. ( 18686378 )
2008
48
Nutraceuticals in Prostate Disease: The Urologist's Role. ( 18836556 )
2008
49
Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases. ( 18668524 )
2008
50
PROBE: patient and physician behaviour and education in prostate disease. ( 18173808 )
2008

Variations for Prostate Disease

Expression for Prostate Disease

Search GEO for disease gene expression data for Prostate Disease.

Pathways for Prostate Disease

GO Terms for Prostate Disease

Cellular components related to Prostate Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell body fiber GO:0070852 8.62 SRD5A1 SRD5A2

Biological processes related to Prostate Disease according to GeneCards Suite gene sharing:

(show all 23)
id Name GO ID Score Top Affiliating Genes
1 transcription initiation from RNA polymerase II promoter GO:0006367 9.77 AR NR1H2 PPARG
2 response to organic cyclic compound GO:0014070 9.77 PPARG SRD5A1 SRD5A2
3 steroid metabolic process GO:0008202 9.75 AKR1C3 SRD5A1 SRD5A2
4 steroid biosynthetic process GO:0006694 9.69 CYP19A1 SRD5A1 SRD5A2
5 steroid hormone mediated signaling pathway GO:0043401 9.67 AR NR1H2 PPARG
6 male gonad development GO:0008584 9.67 AKR1C3 AR SRD5A1 SRD5A2
7 positive regulation of reactive oxygen species metabolic process GO:2000379 9.61 AKR1C3 GADD45A
8 lipid homeostasis GO:0055088 9.61 NR1H2 PPARG
9 male genitalia development GO:0030539 9.58 SRD5A1 SRD5A2
10 hypothalamus development GO:0021854 9.57 SRD5A1 SRD5A2
11 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.56 NR1H2 PPARG
12 androgen biosynthetic process GO:0006702 9.55 SRD5A1 SRD5A2
13 cellular response to testosterone stimulus GO:0071394 9.54 AR SRD5A1
14 prostate gland growth GO:0060736 9.52 AR CYP19A1
15 sex differentiation GO:0007548 9.5 AR SRD5A1 SRD5A2
16 negative regulation of cholesterol storage GO:0010887 9.48 NR1H2 PPARG
17 response to follicle-stimulating hormone GO:0032354 9.46 SRD5A1 SRD5A2
18 negative regulation of interferon-gamma-mediated signaling pathway GO:0060336 9.43 NR1H2 PPARG
19 androgen metabolic process GO:0008209 9.43 CYP19A1 SRD5A1 SRD5A2
20 cellular response to prostaglandin stimulus GO:0071379 9.4 AKR1C3 PPARG
21 progesterone metabolic process GO:0042448 9.33 AKR1C3 SRD5A1 SRD5A2
22 testosterone biosynthetic process GO:0061370 9.13 AKR1C3 CYP19A1 SRD5A2
23 female genitalia development GO:0030540 8.8 CYP19A1 SRD5A1 SRD5A2

Molecular functions related to Prostate Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 steroid hormone receptor activity GO:0003707 9.5 AR NR1H2 PPARG
2 steroid binding GO:0005496 9.43 AR SERPINA6
3 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding GO:0004879 9.43 AR NR1H2 PPARG
4 oxidoreductase activity, acting on the CH-CH group of donors GO:0016627 9.4 SRD5A1 SRD5A2
5 retinoid X receptor binding GO:0046965 9.37 NR1H2 PPARG
6 3-oxo-5-alpha-steroid 4-dehydrogenase activity GO:0003865 9.16 SRD5A1 SRD5A2
7 cholestenone 5-alpha-reductase activity GO:0047751 8.96 SRD5A1 SRD5A2
8 amide binding GO:0033218 8.62 SRD5A1 SRD5A2

Sources for Prostate Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....